admin

I don’t know why anyone would want to buy AT&T (NYSE:T) stock. Source: Roman Tiraspolsky / Shutterstock.com The moves into content by former CEO Randall Stephenson bombed spectacularly. Shareholders are left with $177 billion in debt and, starting next year, a skinnier dividend. The company’s wireless prospects are decent, but only because it can rip
0 Comments
The CEO of the investment firm running the world’s biggest bitcoin fund sounded off on comments made by Securities and Exchange Commission chair Gary Gensler about the likely approval path for the first U.S. bitcoin ETF. Michael Sonnenshein, CEO of Grayscale Investments, warned on Tuesday that the SEC would be making a mistake if it
0 Comments
Coinbase (NASDAQ:COIN) stock enjoys the first-mover advantage with cryptocurrency and has taken crypto mainstream with its user-friendly investment platform. Source: Primakov / Shutterstock.com Bitcoin (CCC:BTC-USD) has attracted massive interest and investment over the last few months. Investors have high hopes on Bitcoin’s price movement, which has driven BTC higher and it has worked in favor
0 Comments
Financial markets love nice round numbers. In early August, COMEX gold futures crossed $2,000 dollars per troy ounce of gold for the first time ever, with the nearby COMEX GC contract for August delivery settling at $2,001. The December 2020 delivery contract reached a price of $2,069 on August 6, before the market came back
0 Comments
With a bipartisan infrastructure bill and a $3.5 trillion budget resolution making their way through Congress and looking poised to pass, I believe investors are greatly underestimating the extent to which these pieces of legislation will help General Electric (NYSE:GE) and GE stock. Source: Sundry Photography / Shutterstock.com GE operates through four industrial segments — Power,
0 Comments
It’s been a little more than three weeks since Zomedica (NYSEAMERICAN:ZOM) reported its Q2 results. Despite reasonably healthy sales, ZOM stock gained just 14% from Aug. 11 through the end of the month.  Source: Postmodern Studio / Shutterstock.com Another InvestorPlace columnist, Ian Bezek, recently argued that Zomedica needs to raise its revenues considerably before investors
0 Comments
Cassava Sciences (NASDAQ:SAVA) stock is in a tailspin after a lab denied it had prepared recent results for the biotech’s experimental Alzheimer’s disease treatment. Source: pathdoc / Shutterstock.com Following the news, Cassava shares fell approximately 50%, eliminating roughly $2.4 billion of value over three trading days. The rejection contradicts a statement from Cassava that Quanterix
0 Comments